Text size :

Andreoni: “Italy in suffering, investments too low compared to Europe”

ADNKRONOS

November 4, 2026

Rome, 4 Nov. (Adnkronos Health) – “Italian research is in great suffering. Investments are too scarce even compared to other European countries: in Italy, only 1.37% of GDP is allocated to research, against a European average of 2.1%. In this scenario, calls for proposals like those from Gilead represent an important example of collaboration between independent public and private research, a synergy that can help keep Italy at the forefront of international research.” This was stated by Massimo Andreoni, emeritus professor of Infectious Diseases at Tor Vergata University in Rome, member of the Superior Health Council and president of the Fellowship Program Judging Committee, speaking at the ‘Generating Innovation. Creating Health’ meeting in Rome, during which the winning projects of the 15th edition of the Gilead Calls were announced.

“Having had the opportunity to participate as a commissioner in several Gilead calls for proposals in recent years, I have been able to observe the very high level of research proposals submitted by Italian researchers. The call has become an anticipated event and a reference point for research in our country,” added Andreoni, emphasizing how the “shortage of funding risks compromising Italy’s ability to maintain its scientific role in fields such as infectiology, oncology, and hematology.” This is a problem that particularly affects new generations. “The lack of funds makes Italy increasingly less attractive for young researchers, who are often forced to go abroad to carry out their activities. This is a trend that must be stopped. Italian researchers have always proven themselves capable of the highest levels of international research, but they need adequate tools, resources, and structures to express their abilities.”

According to Andreoni, it is therefore necessary to “rethink national funding strategies” and strengthen the research system. “We need to obtain funds specifically for research and restructure the facilities where scientific activity takes place, so as to give young people the opportunity to express their talent and once again make Italy a country at the forefront of international research,” he added. The relationship between public and private sectors is also fundamental. “We must change our mindset and consider collaboration between public and private research as added value. The State and institutions should encourage research by pharmaceutical companies and ensure that it integrates more and more with academic research. The potential is very high, but it’s not enough: to achieve results, we need the tools to conduct research,” he concluded.

Jiji Press

Related

Page TOP